Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CCR4 | P51679 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 2/20 | 0.42 |
| ▸ | EDNRB | P24530 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039008 | 0.92 | MEN1 (0.46) | MEN1KMT2ACCR4MAPTKDM4E | |
| SCHEMBL6038440 | 0.84 | KDM4E (0.58) | MEN1KMT2ACCR4MAPTKDM4E | |
| SCHEMBL6038594 | 0.84 | PTGDR2 (0.48) | MEN1KMT2ACCR4KDM4EEDNRA | |
| SCHEMBL6038980 | 0.77 | KDM4E (0.67) | MEN1KMT2ACCR4MAPTKDM4E | |
| SCHEMBL6038816 | 0.77 | CCR4 (0.50) | MEN1KMT2ACCR4MAPTKDM4E | |
| SCHEMBL6038479 | 0.76 | POLB (0.49) | MEN1KMT2ACCR4MAPTKDM4E | |
| SCHEMBL6038323 | 0.75 | KDM4E (0.57) | MEN1KMT2ACCR4MAPTKDM4E | |
| SCHEMBL6038905 | 0.75 | KMT2A (0.68) | MEN1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL6039072 | 0.75 | KMT2A (0.70) | MEN1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL6038783 | 0.75 | PTGDR2 (0.48) | MEN1KMT2ACCR4MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | MEN1 2431/4885KMT2A 4190/4885CCR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.